Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator MyDogBuster, Dip66, locksflooring, roberteliates, HorseShoe Man, sup105
Search This Board:
Last Post: 10/25/2014 4:21:30 AM - Followers: 591 - Board type: Free - Posts Today: 1
MultiCell Technologies (MCET) 
68 Cumberland Street, Suite 301
Woonsocket, RI 02895
 Office: (401) 762-0045



Ticker - MCET (U.S. Reporting: SEC Filer) 

Estimated outstanding shares: 4.3 Billion a/o October 2014

Estimated Float: 3.97 Billion a/o October 2014

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)



Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development

 MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.

                                       MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.

 MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.

 MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

Therapeutic Candidate  


Discovery Optimization    

Preclinical Development    

Phase 1    

Phase 2/b   

Phase 3    



X X X X  



X X      



X X      



X X      

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.

MultiCell Technologies, Inc. Corporate Headquarters

MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.

Find us on Google Maps  

 Management and Board of Directors

Barbara (Corbett) Newmin - Investor Relations

W. Gerald Newmin, Chairman and Chief Executive Officer
Mr. W. Gerald Newmin joined the Company in June 1995.  Mr. Newmin currently serves as Chairman of the Board of Directors and Acting Chief Executive Officer of the Company.  Mr. Newmin is also Chairman and CEO, and a director of Xenogenics Corporation, a majority-owned subsidiary of the Company; Chairman and CEO, and a director of MCT Rhode Island Corp., a wholly-owned subsidiary of the Company; and, CEO and a director of MultiCell Immunotherapeutics, Inc., a majority-owned subsidiary of the Company.  Mr. Newmin has managed NYSE and American Stock Exchange Fortune 500 companies.  Mr. Newmin has been President of Health America Corporation, then the nation’s largest publicly held HMO management company.  Mr. Newmin was Chief Executive Officer and President of The International Silver Company, a diversified multi-national manufacturing company that he restructured.  Mr. Newmin was Chief Operating Officer of numerous Whittaker Corporation operating units, including Production Steel Company, Whittaker Textiles, Bertram Yacht, Trojan Yacht, Columbia Yacht, Narmco Materials and Anson Automotive.  Mr. Newmin was instrumental in Whittaker’s entry into the US and international health care markets.  Mr. Newmin was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States.  Mr. Newmin retired as Chairman and Chief Executive Officer of SYS Technologies, Inc., a high-growth defense technology company in 2003.  Mr. Newmin has a Bachelors degree in Accounting from Michigan State University.

Stephen Chang, PhD (Vice President, Research and Development)
Stephen M. Chang, Ph.D., Director
Dr. Stephen Chang has served as a director of the Company since June 2004.  Dr. Chang has been Chief Scientific Officer (CSO) of Stemgent, Inc. since January 2008.  Prior to joining Stemgent, Dr. Chang served as President and CEO of MultiCell from July 2006 until December 2007, and as President of MultiCell from September 2005 to June 2006.  Prior to joining Multicell, Dr. Chang was the CEO of Astral Immunotherapy which was acquired by Multicell Technologies in September 2005.  Prior to joining Astral, Dr. Chang was CSO and vice president of Canji Inc. / Schering Plough Research Institute in San Diego from 1998 to 2004.  Dr. Chang has also held senior management positions at Chiron and Viagene.  Dr. Chang is currently president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative life saving medications.  Dr. Chang is also a board member of Histogen a privately held company in regenerative medicine.  Dr. Chang earned his doctoral degree in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine.

Grant Miller,  MBA/CFO
Grant Miller, Director
Mr. Miller, appointed to the Board in 2012, received his B.A. from Loma Linda University in Riverside, CA and an MBA in Finance from the University of San Diego, in San Diego, CA. Mr. Miller is Chief Financial & Operating Officer of Sandel Avionics and has served as Chief Financial Officer of Rapid Bridge, LLC, General Manager & Division Controller of Scubapro, Chief Financial Officer of USA Broadband, Inc., Chief Financial Officer & Senior VP Operations of Alitum, and held several positions with WorldXchange and Time Warner Cable, including International Director of Development in Spain and Portugal, Regional Vice President Finance, Corporate Mergers & Acquisitions Analyst, Manager, Finance and Information Systems and Financial Analysis.

Edward Sigmond, Director
Mr. Edward Sigmond has served as a director of the Company since May 2000.  Mr. Sigmond has been in sales, marketing and operations management for the past 20 years.  Mr. Sigmond has served as president of Kestrel Holdings, Inc., a holding company, since its inception in 1997.  Mr. Sigmond served as president of Kestrel Development, a Texas based real estate development company, from 1993 to 1998 when it was dissolved.  Mr. Sigmond studied Marketing and Chemistry at Duquesne University.

Thomas A. Page, Director
Mr. Thomas Page has served as a director of the Company since September 2003.  Mr. Page is Director Emeritus and former Chairman of the Board and CEO of Enova Corporation and San Diego Gas and Electric Company (now part of Sempra Energy).  Prior to the formation of Sempra Energy Corporation as a holding company in 1996, at various times Mr. Page was SDG&E’s chairman, president and CEO and  held one or more of these positions until his retirement in 1998.  Mr. Page joined SDG&E in 1978 as executive vice president and COO.  In 1981, he was elected president and CEO and added the chairmanship in 1983.  Mr. Page has been active in numerous industrial, community and governmental associations and has funded medical research.  He is a director of the San Diego Regional Economic Development Corporation, Community National Bank, Sys Technologies and is an advisory director of Sorrento Ventures.  Mr. Page earned a Bachelor of Science degree in civil engineering, a masters degree in industrial administration and was awarded a doctorate in management, all from Purdue University.  Mr. Page has been licensed as an engineer and as a certified public accountant (CPA).  Mr. Page also serves on the University of California Presidents Council on the National Laboratories.

Scientific Advisors

Alan Tuchman, M.D.
Dr. Tuchman is concurrently in private practice and is Clinical Professor of Neurology at New York Medical College.  He is also the Principal of a healthcare and neuroscience consulting firm.  From 1997 to 2001, Dr. Tuchman was Senior Vice President of Equity Research for Oscar Gruss & Son (Member of the New York Stock Exchange), New York, New York, where he conducted investment research in medical and biotechnology and helped develop marketing strategies for healthcare companies.  Prior to this, he was Vice Dean of Clinical Affairs for New York Medical College where he developed and directed clinical care and medical education policy for 29 affiliated hospitals and served as Professor and Vice Chairman and Program Director for Neurology Residency in the Department of Neurology at the same institution.  At the Lincoln Medical and Mental Health Center, Dr. Tuchman held the positions of Medical Director for the 560-bed hospital from 1990 to 1991 and Director of the Department of Neurology from 1979 to 1994.  Serving in the United States Air Force as Major, he was Chief of Neurology Service for a 16-state region.  Dr. Tuchman earned his B.S. in Chemistry in 1968 from the City College of New York, his M.D. in 1972 from the University of Cincinnati College of Medicine, and his MBA from Columbia University in 1996. He completed his internship at New York Medical College and his residency at the Mount Sinai Hospitals Department of Neurology.  Dr. Tuchman was a clinical fellow in multiple sclerosis at the Albert Einstein College of Medicine Department of Neurology.  Dr. Tuchman is certified by the American Board of Psychiatry and Neurology and the American Society of Neurorehabilitation and is licensed in New York, New Jersey and Ohio.  Dr. Tuchman served as the President of the Epilepsy Society of Southern New York from 1987 1992.



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MCET News: Quarterly Report (10-q) 10/15/2014 12:34:25 PM
MCET News: MultiCell Technologies Granted U.S. Patent Covering Therapeutics Which Fight Virus Infection And Cancer 08/25/2014 08:51:00 AM
MCET News: Confidential Treatment Order (ct Order) 08/21/2014 09:53:41 AM
MCET News: Quarterly Report (10-q) 07/15/2014 09:15:45 AM
#38341  Sticky Note For those Who is Long investor and lost sup105 09/08/14 01:57:55 PM
#34376  Sticky Note MultiCell Technologies, Inc. OTCQB TraderpennyX 04/03/14 03:57:31 AM
#27347  Sticky Note PATENT INFORMATION roberteliates 03/28/13 07:50:04 AM
#38950   He is a cro and try to swallow gggamm338 10/25/14 04:21:29 AM
#38948   SW said he has none position at all gggamm338 10/24/14 10:02:25 PM
#38947   Just one guy with BA acc Then , gggamm338 10/24/14 09:32:09 PM
#38946   The number of shares traded in a single simon wagstaff 10/24/14 04:04:56 PM
#38945   Simon ,are you kidding me, all penny sharki 10/24/14 03:54:22 PM
#38944   It doesn't take any time and anybody who simon wagstaff 10/24/14 03:32:03 PM
#38943   Sharki - as a long term shareholder of Dip66 10/24/14 03:00:02 PM
#38942   Oh, now i see, you Simon considered yourself sharki 10/24/14 02:39:35 PM
#38941   I am not "vomiting" on your "investment", just simon wagstaff 10/24/14 01:16:09 PM
#38940   And the end result? Any real value at simon wagstaff 10/24/14 12:59:18 PM
#38939   Not surprising {caunt bother to look}coming from someone sharki 10/24/14 12:13:52 PM
#38938   Unmet medical needs, for sure. simon wagstaff 10/24/14 12:00:47 PM
#38937   "Why pump so hard" ztek 10/24/14 11:51:22 AM
#38936   I can't bother to look, what day was simon wagstaff 10/24/14 11:02:54 AM
#38935   Simon, why is it you keep on sharki 10/24/14 10:53:20 AM
#38934   No trade in 40 minute…last trade was 50000 ferenc 10/24/14 10:52:05 AM
#38933   It's very easy to check. Don't take my simon wagstaff 10/24/14 10:12:27 AM
#38932   Yahoo shows 4.33 billion shares outstanding as well. ztek 10/24/14 09:58:38 AM
#38931   Fidelity shows 4.329 billion shares outstanding. I don't simon wagstaff 10/24/14 08:02:32 AM
#38930   4.3 billion or so issued, 5 billion authorized. simon wagstaff 10/24/14 07:36:41 AM
#38929   As quoted from the 10-Q . . . bontooth 10/24/14 02:46:08 AM
#38927   Selling stopped , huge patent and interest growing newlonginvest 10/23/14 08:11:10 PM
#38926   who cares at this point what MultiSmell is Dip66 10/23/14 07:25:58 PM
#38925   700 million shares to go? simon wagstaff 10/23/14 05:14:48 PM
#38924   imo the next PR is in November bontooth 10/23/14 03:08:19 PM
#38923   Has MultiCell blocked all of their shareholders at Dip66 10/23/14 02:18:32 PM
#38922   Come on VNDM...go and find your home elsewhere. BigMoneyAtl 10/23/14 10:47:09 AM
#38921   Still only one patent directly assigned to MCET. simon wagstaff 10/23/14 07:46:26 AM
#38920   MCET will not go out of business either. HorseShoe Man 10/23/14 07:01:53 AM
#38919   In my opinion MCET is ready to sell HorseShoe Man 10/23/14 06:35:16 AM
#38918   HorseShoe Man . . need your opinion bontooth 10/23/14 01:54:25 AM
#38917   That also might be why there was that HorseShoe Man 10/22/14 09:32:43 PM
#38916   Looks like he's getting ready to sell to me HorseShoe Man 10/22/14 09:28:56 PM
#38915   The Income Statement on Yahoo finance is interesting ztek 10/22/14 09:09:35 PM
#38914   What a bunch of Rah rah and no bluejacket6 10/22/14 04:02:06 PM
#38913   Funny trading?? HorseShoe Man 10/22/14 03:53:51 PM
#38912   VFIN gone from the 6s. Only a few GoldMiner 10/22/14 03:44:00 PM
#38911   Odd, I just purchased bontooth 10/22/14 03:03:26 PM
#38910   i'm project a bottom of 0003 then recover REDZONE 10/22/14 02:10:00 PM
#38909   They only have about 300-400mil to sell REDZONE 10/22/14 02:09:13 PM
#38908   BUY and hold until NEWS .0014-.0015 typical high here REDZONE 10/22/14 01:53:33 PM
#38907   7s are so thin. We can easily hit GoldMiner 10/22/14 01:43:49 PM
#38906   Red just had to add you to the ctvette2003 10/22/14 01:03:42 PM
#38905   lets push it to .0008 REDZONE 10/22/14 12:48:00 PM
#38904   Buying at .0005 and selling .0006? REDZONE 10/22/14 12:47:47 PM
#38903   In at .0006 looking for .0008-.0009 REDZONE 10/22/14 12:01:18 PM
#38902   Zero Fda approval, nothing to approve, or even simon wagstaff 10/22/14 11:50:24 AM
#38901   we need to get the word out volume REDZONE 10/22/14 11:41:37 AM
#38900   .0005s seems to be bottom who knows REDZONE 10/22/14 11:40:41 AM
#38899   BIO companies unfortunately are cash poor until FDA REDZONE 10/22/14 11:39:04 AM